Clinical pharmacokinetics of levorotatory and racemic disopyramide, at steady state, following oral administration in patients with ventricular arrhythmias.

Journal of Clinical Pharmacology
P Le CorreR Le Verge

Abstract

Electrophysiological effects, antiarrhythmic activity and kinetics of levorotatory disopyramide (R(-) DP) and racemic disopyramide (equimolar mixture of R(-) DP and S(+) DP) were compared in patients with ventricular arrhythmias. This double blind cross-over randomized trial was achieved, at steady-state, following oral administration of 200 mg three times a day. In comparison with baseline values, electrophysiological data indicated that R(-) DP and racemic DP prolonged, significantly and similarly, PR interval (+11.7% and +10%, respectively, P less than .01), and QTc interval (+9.2% and +7%, respectively, P less than .001), while QRS interval was not significantly affected. The antiarrhythmic activity, assessed by percent reduction in ventricular extrasystoles frequency, showed a similar efficiency of levorotatory and racemic DP: 80% and 74%, respectively (P = .24). Ventricular tachycardias disappeared with both treatments in the three patients concerned. During the racemic period, the mean total plasma clearance, expressed as CL/F, of S(+) DP (114.6 ml/min), was significantly lower than that of R(-) DP (157 ml/min), (P less than .001). The mean total plasma clearance of R(-) DP, during the levorotatory period (163 ml/min), d...Continue Reading

References

Feb 1, 1979·Journal of Pharmacokinetics and Biopharmaceutics·P J MeffinD C Harrison
Jun 15, 1978·European Journal of Pharmacology·A M GrantS I Ankier
Nov 1, 1978·British Journal of Clinical Pharmacology·S M BrysonJ R Lawrence
Jul 1, 1976·American Heart Journal·A P Niarchos
Jun 1, 1976·Journal of Pharmacokinetics and Biopharmaceutics·P H Hinderling, E R Garrett
May 1, 1987·Journal of Cardiovascular Pharmacology·J J Lima, H Boudoulas
Jan 1, 1988·European Journal of Clinical Pharmacology·K EndresenK Forfang
Apr 1, 1988·Journal of Clinical Pharmacology·E V CapparelliM S Chow
May 1, 1986·Clinical Pharmacokinetics·L A Siddoway, R L Woosley
Aug 1, 1986·Journal of Pharmacokinetics and Biopharmaceutics·K M GiacominiT F Blaschke
Jul 1, 1985·Clinical Pharmacology and Therapeutics·W T ChiangK Schenck-Gustafsson
Mar 1, 1974·American Heart Journal·B N Singh, O Hauswirth
Nov 1, 1974·Journal of Pharmaceutical Sciences·P H HinderlingE R Garrett
Sep 18, 1965·Nature·J G WagnerO S Carpenter
Feb 1, 1984·European Heart Journal·E M Vaughan Williams
Dec 1, 1984·Journal of Pharmacokinetics and Biopharmaceutics·M ThibonnierR L Williams
Aug 20, 1984·Life Sciences·J J LimaL W Robertson
Nov 1, 1984·British Journal of Clinical Pharmacology·J E Bredesen, P Kierulf
Nov 1, 1982·British Journal of Clinical Pharmacology·J E BredesenP K Lunde
Jan 1, 1980·British Journal of Clinical Pharmacology·B WhitingL B Sheiner
Feb 1, 1980·British Journal of Clinical Pharmacology·M L Aitio, T Vuorenmaa

❮ Previous
Next ❯

Citations

Mar 1, 1996·Journal of Cardiovascular Pharmacology·M NakamuraK Hashimoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.